Elena Martínez-Robles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena Martínez-Robles has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Ramos Ibáñez
Ingeniero Informático, Universidad de Zaragoza , Zaragoza
2 shared publications - Gema María Lledó-Ibáñez
Hospital Clínic de Barcelona, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS)
2 shared publications - Jorge Álvarez Troncoso
Systemic Immune-Mediated Diseases Unit, Internal Medicine Department, Hospital Universitario La Paz, IDIPAZ, Madrid, Spain
2 shared publications A. Noblejas Mozo
Hospital Universitario La Paz, Internal Medicine, Madrid, Spain
1 shared publicationAdela Marín
Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa , Zaragoza
1 shared publication- Alfredo Guillén-Del-Castillo
Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Quantitative nailfold videocapillaroscopy is associated with disease activity in idiopathic inflammatory myopathies: the CapIAMI registry
Objective. To assess whether quantitative nailfold videocapillaroscopy (NVC) findings are associated with clinician-assessed disease activity in idiopathic inflammatory myopathies (IIM), and how this association varies with Raynaud phenomenon (RP) status and IIM subtype.Methods. Cross-sectional analysis of the CapIAMI registry: 413 adults with IIM (2017 EULAR/ACR criteria) from 27 centres in 9 countries. NVC was performed regardless of RP status and quantified centrally with a validated deep-learning platform; incomplete laboratory panels were multiply imputed so all patients contributed. Associations with activity were examined by univariate comparison, logistic regression and Random Forest, with prespecified analyses by IIM subtype and RP status.Results. Disease was active in 265/413 patients (64.2%). Active disease was associated with lower capillary density, more giant capillaries, more microhaemorrhages, and more abnormal (neoangiogenic) shapes (all p<0.01). With all 413 patients included using multiple imputation, NVC alone and the laboratory panel discriminated similarly (AUC 0.66 vs 0.63, DeLong p=0.48); a non-linear model using both reached 0.77 and exceeded the panel (Holm p<0.001). Activity prevalence and NVC severity differed across IIM subtypes (both p<0.05). Only 117/413 (28.3%) had documented RP, yet 36% of RP-negative patients showed a scleroderma-spectrum pattern. NVC severity also tracked the number of active organ domains.Conclusion. Quantitative NVC findings are associated with clinician-assessed disease activity in IIM, and both the magnitude and pattern of this association vary by IIM subtype and RP status. Microvascular abnormalities are detectable in many RP-negative patients, supporting broader consideration of NVC in IIM beyond those presenting with RP.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessQuantitative nailfold videocapillaroscopy is associated with disease activity in idiopathic inflammatory myopathies: the CapIAMI registry
Objective. To assess whether quantitative nailfold videocapillaroscopy (NVC) findings are associated with clinician-assessed disease activity in idiopathic inflammatory myopathies (IIM), and how this association varies with Raynaud phenomenon (RP) status and IIM subtype.Methods. Cross-sectional analysis of the CapIAMI registry: 413 adults with IIM (2017 EULAR/ACR criteria) from 27 centres in 9 countries. NVC was performed regardless of RP status and quantified centrally with a validated deep-learning platform; incomplete laboratory panels were multiply imputed so all patients contributed. Associations with activity were examined by univariate comparison, logistic regression and Random Forest, with prespecified analyses by IIM subtype and RP status.Results. Disease was active in 265/413 patients (64.2%). Active disease was associated with lower capillary density, more giant capillaries, more microhaemorrhages, and more abnormal (neoangiogenic) shapes (all p<0.01). With all 413 patients included using multiple imputation, NVC alone and the laboratory panel discriminated similarly (AUC 0.66 vs 0.63, DeLong p=0.48); a non-linear model using both reached 0.77 and exceeded the panel (Holm p<0.001). Activity prevalence and NVC severity differed across IIM subtypes (both p<0.05). Only 117/413 (28.3%) had documented RP, yet 36% of RP-negative patients showed a scleroderma-spectrum pattern. NVC severity also tracked the number of active organ domains.Conclusion. Quantitative NVC findings are associated with clinician-assessed disease activity in IIM, and both the magnitude and pattern of this association vary by IIM subtype and RP status. Microvascular abnormalities are detectable in many RP-negative patients, supporting broader consideration of NVC in IIM beyond those presenting with RP.
- 3 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 124
Myocarditis in idiopathic inflammatory myopathies: serologic and clinical correlates in a single-center registry
To characterize the clinical and serological correlates of cardiovascular magnetic resonance (CMR)-confirmed myocarditis in idiopathic inflammatory myopathies (IIM), evaluate the diagnostic performance of high-sensitivity cardiac troponin I (hs-TnI), and quantify the independent prognostic impact of myocarditis relative to interstitial lung disease (ILD). Single-center retrospective cohort study (STROBE-compliant) of 142 consecutive adults with IIM (2019–2025). Myocarditis was confirmed by CMR according to the 2018 Lake Louise Criteria, performed both at diagnosis and during follow-up (with or without immunosuppression) upon clinical suspicion and/or elevated hs-TnI. Myositis-specific antibodies (MSA), myositis-associated antibodies (MAA), anti-Ro52 and antiphospholipid antibodies (aPL, Sydney criteria: ≥40 GPL/MPL units confirmed at ≥ 12 weeks) were systematically recorded. Associations were assessed with Fisher’s exact test and logistic regression; multivariable models were pre-specified as parsimonious (two predictors) given the limited event count. Overall survival was analyzed with Kaplan–Meier curves, the log-rank test and Cox proportional-hazards regression. Myocarditis was confirmed in 9/142 patients (6.3%), without significant association with IIM class (P = 0.303) or with the antisynthetase antibody subgroup (anti-Jo-1 + PL-12 + PL-7 + EJ; 5.8% vs. 6.7%, P = 1.000). In univariable analyses, myocarditis was associated with Raynaud phenomenon (OR 13.6, 95% CI 2.3–80.0), aPL positivity (OR 10.7, 95% CI 2.6–43.9), anti-Ro52 coexisting with MSA/MAA (OR 8.7, 95% CI 2.2–34.8), anti-PM/Scl (OR 7.1, 95% CI 1.6–30.3), fever (OR 7.1, 95% CI 1.6–30.3) and ILD (OR 4.7, 95% CI 1.1–20.3). hs-TnI was markedly higher in myocarditis (median 366 vs. 3.5 ng/L; P < 0.001) with an area under the receiver-operating characteristic curve (AUROC) of 0.91 (95% CI 0.83–0.98). In the event-constrained multivariable model, Raynaud phenomenon (adjusted OR 13.1, 95% CI 1.5–112.7) and aPL (adjusted OR 7.2, 95% CI 1.4–36.0) remained independently associated. All-cause mortality was higher in myocarditis (44% vs. 9%; OR 7.95, 95% CI 2.0–31.5; log-rank P = 0.030; univariable Cox HR 3.77, 95% CI 1.03–13.78; P = 0.044), and persisted after adjustment for ILD in the logistic model (adjusted OR 5.9, 95% CI 1.3–26.1; P = 0.020), whereas ILD attenuated to a non-significant trend (adjusted OR 2.9, 95% CI 0.9–9.2; P = 0.073). In this single-center retrospective cohort, IIM-associated myocarditis was consistently associated with Raynaud phenomenon, aPL positivity and anti-Ro52 coexistence, and was associated with higher mortality than ILD. These findings support hs-TnI-guided triage to CMR as part of systematic cardiac surveillance in IIM, pending multicenter confirmation.
- 3 June 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 124
Myocarditis in idiopathic inflammatory myopathies: serologic and clinical correlates in a single-center registry
To characterize the clinical and serological correlates of cardiovascular magnetic resonance (CMR)-confirmed myocarditis in idiopathic inflammatory myopathies (IIM), evaluate the diagnostic performance of high-sensitivity cardiac troponin I (hs-TnI), and quantify the independent prognostic impact of myocarditis relative to interstitial lung disease (ILD). Single-center retrospective cohort study (STROBE-compliant) of 142 consecutive adults with IIM (2019–2025). Myocarditis was confirmed by CMR according to the 2018 Lake Louise Criteria, performed both at diagnosis and during follow-up (with or without immunosuppression) upon clinical suspicion and/or elevated hs-TnI. Myositis-specific antibodies (MSA), myositis-associated antibodies (MAA), anti-Ro52 and antiphospholipid antibodies (aPL, Sydney criteria: ≥40 GPL/MPL units confirmed at ≥ 12 weeks) were systematically recorded. Associations were assessed with Fisher’s exact test and logistic regression; multivariable models were pre-specified as parsimonious (two predictors) given the limited event count. Overall survival was analyzed with Kaplan–Meier curves, the log-rank test and Cox proportional-hazards regression. Myocarditis was confirmed in 9/142 patients (6.3%), without significant association with IIM class (P = 0.303) or with the antisynthetase antibody subgroup (anti-Jo-1 + PL-12 + PL-7 + EJ; 5.8% vs. 6.7%, P = 1.000). In univariable analyses, myocarditis was associated with Raynaud phenomenon (OR 13.6, 95% CI 2.3–80.0), aPL positivity (OR 10.7, 95% CI 2.6–43.9), anti-Ro52 coexisting with MSA/MAA (OR 8.7, 95% CI 2.2–34.8), anti-PM/Scl (OR 7.1, 95% CI 1.6–30.3), fever (OR 7.1, 95% CI 1.6–30.3) and ILD (OR 4.7, 95% CI 1.1–20.3). hs-TnI was markedly higher in myocarditis (median 366 vs. 3.5 ng/L; P < 0.001) with an area under the receiver-operating characteristic curve (AUROC) of 0.91 (95% CI 0.83–0.98). In the event-constrained multivariable model, Raynaud phenomenon (adjusted OR 13.1, 95% CI 1.5–112.7) and aPL (adjusted OR 7.2, 95% CI 1.4–36.0) remained independently associated. All-cause mortality was higher in myocarditis (44% vs. 9%; OR 7.95, 95% CI 2.0–31.5; log-rank P = 0.030; univariable Cox HR 3.77, 95% CI 1.03–13.78; P = 0.044), and persisted after adjustment for ILD in the logistic model (adjusted OR 5.9, 95% CI 1.3–26.1; P = 0.020), whereas ILD attenuated to a non-significant trend (adjusted OR 2.9, 95% CI 0.9–9.2; P = 0.073). In this single-center retrospective cohort, IIM-associated myocarditis was consistently associated with Raynaud phenomenon, aPL positivity and anti-Ro52 coexistence, and was associated with higher mortality than ILD. These findings support hs-TnI-guided triage to CMR as part of systematic cardiac surveillance in IIM, pending multicenter confirmation.
- Top Cited PapersOpen Access
- 7 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3667-3675
CAPI-Detect: machine learning in capillaroscopy reveals new variables influencing diagnosis
Objectives: Nailfold videocapillaroscopy (NVC) is the gold standard for diagnosing SSc and differentiating primary from secondary RP. The CAPI-Score algorithm, designed for simplicity, classifies capillaroscopy scleroderma patterns (CSPs) using a limited number of capillary variables. This study aims to develop a more advanced machine learning (ML) model to improve CSP identification by integrating a broader range of statistical variables while minimizing examiner-related bias. Methods: A total of 1780 capillaroscopies were randomly and blindly analysed by three to four trained observers. Consensus was defined as agreement among all but one observer (partial consensus) or unanimous agreement (full consensus). Capillaroscopies with at least partial consensus were used to train ML-based classification models using CatBoost software, incorporating 24 capillary architecture-related variables extracted via automated NVC analysis. Validation sets were employed to assess model performance. Results: Of the 1490 capillaroscopies classified with consensus, 515 achieved full consensus. The model, evaluated on partial and full consensus datasets, achieved 0.912, 0.812 and 0.746 accuracy for distinguishing SSc from non-SSc, among SSc patterns, and between normal and non-specific patterns, respectively. When evaluated on full consensus only, accuracy improved to 0.910, 0.925 and 0.933. CAPI-Detect outperformed CAPI-Score, revealing novel capillary variables critical to ML-based classification. Conclusions: CAPI-Detect, an ML-based model, provides an unbiased, quantitative analysis of capillary structure, shape, size and density, significantly improving capillaroscopic pattern identification.
- 7 February 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (6) , 3667-3675
Top Cited PapersOpen AccessCAPI-Detect: machine learning in capillaroscopy reveals new variables influencing diagnosis
Objectives: Nailfold videocapillaroscopy (NVC) is the gold standard for diagnosing SSc and differentiating primary from secondary RP. The CAPI-Score algorithm, designed for simplicity, classifies capillaroscopy scleroderma patterns (CSPs) using a limited number of capillary variables. This study aims to develop a more advanced machine learning (ML) model to improve CSP identification by integrating a broader range of statistical variables while minimizing examiner-related bias. Methods: A total of 1780 capillaroscopies were randomly and blindly analysed by three to four trained observers. Consensus was defined as agreement among all but one observer (partial consensus) or unanimous agreement (full consensus). Capillaroscopies with at least partial consensus were used to train ML-based classification models using CatBoost software, incorporating 24 capillary architecture-related variables extracted via automated NVC analysis. Validation sets were employed to assess model performance. Results: Of the 1490 capillaroscopies classified with consensus, 515 achieved full consensus. The model, evaluated on partial and full consensus datasets, achieved 0.912, 0.812 and 0.746 accuracy for distinguishing SSc from non-SSc, among SSc patterns, and between normal and non-specific patterns, respectively. When evaluated on full consensus only, accuracy improved to 0.910, 0.925 and 0.933. CAPI-Detect outperformed CAPI-Score, revealing novel capillary variables critical to ML-based classification. Conclusions: CAPI-Detect, an ML-based model, provides an unbiased, quantitative analysis of capillary structure, shape, size and density, significantly improving capillaroscopic pattern identification.
- 19 December 2023
- Published by Elsevier in Revista Clínica Española
- Vol. 223, S215-S216
1727 - SÍNDROME SICCA: CORRELACIÓN GAMMAGRÁFICA, CLÍNICA E HISTOLÓGICA
- 19 December 2023
- Published by Elsevier in Revista Clínica Española
- Vol. 223, S215-S216
1727 - SÍNDROME SICCA: CORRELACIÓN GAMMAGRÁFICA, CLÍNICA E HISTOLÓGICA
- Open Access
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 693-694
POS0875 MYOSITIS-SPECIFIC ANTIBODIES IN A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY
Background: Myositis-specific antibodies (MSA) are highly specific and useful to classify patients as having syndromes with distinct clinical features and prognosis. MSA are almost always mutually exclusive and quite specific, adding value as a useful biomarker for diagnosis. Although individual autoantibodies aren’t sensitive enough to detect the full spectrum of idiopathic inflammatory myopathies (IIM), the sensitivity of a myositis panel is increasing as more autoantibodies are discovered, and as better assays become available. Objectives: We aimed to analyze the usefulness of a myositis-specific immunoblot for the diagnosis of IIM in a hospital cohort from January 2019 to December 2020. We also seek to correlate immunological findings with the risk of associated interstitial lung disease (ILD), cancer, or death. Methods: Retrospective single-center observational study conducted in a Spanish tertiary hospital. In patients with high clinical suspicion of IIM, a myositis immunoblot was performed including Jo1, PL-7, PL-12, EJ, SRP, Mi2, Ku, MDA-5, TIF1-γ, HMGCR, PM-Scl and Ro52 antibodies. The demographic characteristics, the risk of ILD, cancer and death were analyzed. Results: In a cohort of 313 patients with high suspicion of IIM, 87 patients (27.8%) presented a positive MSA (MSA+ve). The mean age at diagnosis was 56.7±16.9 years, with no significant differences between MSA+ve and MSA-ve (p=0.597). Most of the patients were women with significant differences between both groups (80.5% MSA+ve vs 68.1% MSA-ve, p=0.030). IIM were classified as antisynthetase syndrome (ARS) (38%), dermatomyositis (DM) (31%), overlap myopathy (OM) (16.9%) and necrotizing myopathy (NM) (14.1%) according to the manifestations and MSA found (Jo1, PL-12, PL-7, EJ in ARS; Mi-2, MDA-5 and TIF1-γ in DM; Ku and PM-Scl in OM; HMGCR and SRP in NM). The most frequent MSA were anti-Jo1 (16.9%), TIF1-γ (15.5%), Ku (12.7%), Mi-2 (9.9%), PL-7 (9.9%), HMCGR (8.5%), PL-12 (7%), MDA-5 (5.6%), SRP (5.6%) and EJ (4.2%). The presence of Ro52 associated with other MSA was found in 20 patients (22.9%). ILD was the most frequent manifestation (45.2% of the MSA+ve). Non-specific interstitial pneumonia (NSIP) was the most frequent ILD (39.5%), followed by usual interstitial pneumonia (34.2%). The main risk factors associated with IIM-ILD were some subtypes of the MSAs (pConclusion: The use of a myositis blot allowed classifying, stratifying the risk of ILD, the risk of cancer and the risk of mortality in IIM. IIM-ILD was the most frequent complication, usually manifested as NSIP. The associated risk factors were ARS, OM, some MSAs, Ro52+ and older age. Cancer was a serious and frequent manifestation in these patients, especially in patients with TIF1-γ and other MSAs, so it is essential to know the risk factors and perform an early screening, especially in older patients. A better knowledge of the serological profiles of IIM will provide more individualized approaches and better risk stratification, helping in the management and treatment of these patients. References: [1]Satoh et al. Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. [2]Betteridge et al. J Intern Med. 2016 Jul;280(1):8-23. Disclosure of Interests: None declared
- 1 June 2021
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 80 (Suppl 1) , 693-694
Open AccessPOS0875 MYOSITIS-SPECIFIC ANTIBODIES IN A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY
Background: Myositis-specific antibodies (MSA) are highly specific and useful to classify patients as having syndromes with distinct clinical features and prognosis. MSA are almost always mutually exclusive and quite specific, adding value as a useful biomarker for diagnosis. Although individual autoantibodies aren’t sensitive enough to detect the full spectrum of idiopathic inflammatory myopathies (IIM), the sensitivity of a myositis panel is increasing as more autoantibodies are discovered, and as better assays become available. Objectives: We aimed to analyze the usefulness of a myositis-specific immunoblot for the diagnosis of IIM in a hospital cohort from January 2019 to December 2020. We also seek to correlate immunological findings with the risk of associated interstitial lung disease (ILD), cancer, or death. Methods: Retrospective single-center observational study conducted in a Spanish tertiary hospital. In patients with high clinical suspicion of IIM, a myositis immunoblot was performed including Jo1, PL-7, PL-12, EJ, SRP, Mi2, Ku, MDA-5, TIF1-γ, HMGCR, PM-Scl and Ro52 antibodies. The demographic characteristics, the risk of ILD, cancer and death were analyzed. Results: In a cohort of 313 patients with high suspicion of IIM, 87 patients (27.8%) presented a positive MSA (MSA+ve). The mean age at diagnosis was 56.7±16.9 years, with no significant differences between MSA+ve and MSA-ve (p=0.597). Most of the patients were women with significant differences between both groups (80.5% MSA+ve vs 68.1% MSA-ve, p=0.030). IIM were classified as antisynthetase syndrome (ARS) (38%), dermatomyositis (DM) (31%), overlap myopathy (OM) (16.9%) and necrotizing myopathy (NM) (14.1%) according to the manifestations and MSA found (Jo1, PL-12, PL-7, EJ in ARS; Mi-2, MDA-5 and TIF1-γ in DM; Ku and PM-Scl in OM; HMGCR and SRP in NM). The most frequent MSA were anti-Jo1 (16.9%), TIF1-γ (15.5%), Ku (12.7%), Mi-2 (9.9%), PL-7 (9.9%), HMCGR (8.5%), PL-12 (7%), MDA-5 (5.6%), SRP (5.6%) and EJ (4.2%). The presence of Ro52 associated with other MSA was found in 20 patients (22.9%). ILD was the most frequent manifestation (45.2% of the MSA+ve). Non-specific interstitial pneumonia (NSIP) was the most frequent ILD (39.5%), followed by usual interstitial pneumonia (34.2%). The main risk factors associated with IIM-ILD were some subtypes of the MSAs (pConclusion: The use of a myositis blot allowed classifying, stratifying the risk of ILD, the risk of cancer and the risk of mortality in IIM. IIM-ILD was the most frequent complication, usually manifested as NSIP. The associated risk factors were ARS, OM, some MSAs, Ro52+ and older age. Cancer was a serious and frequent manifestation in these patients, especially in patients with TIF1-γ and other MSAs, so it is essential to know the risk factors and perform an early screening, especially in older patients. A better knowledge of the serological profiles of IIM will provide more individualized approaches and better risk stratification, helping in the management and treatment of these patients. References: [1]Satoh et al. Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. [2]Betteridge et al. J Intern Med. 2016 Jul;280(1):8-23. Disclosure of Interests: None declared